risdiplam result continu impress
roche/ptc report babi sit unassist second
babi abl sit without support one patient even
achiev abil stand result compar favor
risdiplam result babi sat unassist babi could
sit without support spinraza endear trial patient
abl sit independ one patient risdiplam even achiev
abil stand risdiplam chop-intend improv consist
seen median chang chop-intend
pt month median chang point
babi experienc fatal complic event rate appear
compar seen spinraza endear trial
surviv trial durat look forward detail event
host even
rais target price reflect grow
confid commerci opportun addit favor
efficaci signal believ risdiplam oral administr
differenti drug spinraza administ via chronic intrathec
inject increas tp model risdiplam
captur market share type opportun
market share type popul reflect belief
risdiplam use patient unabl receiv gene therapi due
antibodi reimburs issu previous
treat zolgensma experi incomplet respons
wane efficaci time expect potenti occur minor
patient also expect risdiplam cost-effect older
preval type popul ep vs old risk
includ clinic regulatori commerci headwind
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
biotechnolog compani focus
develop manufactur small molecul therapeut
address multipl area includ rare disord oncolog
price may rate outperform target price analyst martin auster
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
 close
blue sky valuat base probabl
success risdiplam stabl translarna sale post
po aadc gene therapi
grey sky valuat assum valu risdiplam
 premium
risdiplam sunfish result consist roche/ptc report
type patient saw improv least point scale
baselin month includ among patient year old
age year recal patient saw least point improv
month challeng compar result
zolgensma spinraza trial use hfmse vs enrol younger
patient yr old vs yr old believ data support least
compar profil product
compani mention price
